- BPC-157 has the largest preclinical literature of the five and no published controlled human trial of tissue repair.
- The human trials people cite for TB-500 used full-length thymosin beta-4, not the fragment, and tested dry eye and venous leg ulcers.
- GHK-Cu's human data is almost all topical: one positive trial in diabetic foot ulcers and one facial trial that found no objective benefit.
- KPV has preclinical gut-inflammation work and no published human study of its own.
- Thymosin alpha-1 is the only one licensed as a medicine anywhere (as Zadaxin, for hepatitis), and it is not FDA-approved.
"Healing peptides" covers five compounds that people mention together and that have very different evidence behind them. This page sets them side by side by what was actually studied: in which tissue, in whom, and with what result. It does not rank them, because the research does not support ranking them for anyone.
Tissue repair is several processes in sequence: new blood vessels, immune cells arriving, collagen being laid down, and the tissue remodelling. Each of these compounds is proposed to act on a different step. A proposed mechanism is a reason a compound was studied, not evidence that it works in people.
The pair discussed most for injuries
Most of their tissue-repair research is preclinical; neither has a completed human efficacy trial.
Skin, scars and connective tissue
Studied for skin and the collagen under it, mostly in topical and preclinical work.
Gut lining and immune
Studied for the gut wall and for immune signalling rather than for joints.
1. BPC-157: a large preclinical literature, almost no human data
BPC-157 is a 15-amino-acid peptide isolated from human gastric juice. In preclinical models it has been reported to speed repair of tendon, ligament, muscle and gut lining, and researchers attribute that mainly to nitric oxide signalling and new blood-vessel growth. PubMed indexed 224 BPC-157 papers as of August 2026, and none is indexed as a clinical trial.
The human record is small: a two-person intravenous safety pilot (2025), a 12-person knee-pain chart review with no control group (2021), an inflammatory bowel trial under the name PL-14736 whose results were never published as a standalone paper, and a randomized hamstring trial that has been recruiting since February 2026. It is not an approved medicine anywhere and is prohibited in sport at all times.
2. TB-500: the human trials used a different molecule
TB-500 is a seven-amino-acid fragment of thymosin beta-4, a 43-amino-acid protein the body makes that helps cells move by binding actin. The two are different molecules and are often referred to by the same name. The human trials that exist used the full protein, as eye drops for severe dry eye and as a topical treatment for venous leg ulcers. Nobody has published a human trial of either molecule for tendon or muscle injury. TB-500 is named on the WADA prohibited list.
3. GHK-Cu: human data, almost all of it on skin
GHK-Cu is a copper-binding tripeptide found in human blood. Lab studies report effects on collagen and elastin production and on the expression of many repair-related genes. Unusually for this group, it has human trials, and nearly all of them are topical. The strongest positive result is a randomized, placebo-controlled trial of a topical gel in diabetic foot ulcers. In fifty years there has been one randomized controlled trial of GHK-Cu on facial skin, and it found no objective benefit. No published human trial has studied GHK-Cu given by injection.
4. KPV: gut-inflammation work with no human study
KPV is a three-amino-acid fragment of alpha-MSH. In preclinical models of colitis and in human cell lines it reduced inflammatory signalling, mainly through the NF-kB pathway, and most of the work concerns the gut because the transporter that carries KPV into cells is a gut transporter. There is no published human study of KPV. Papers using human cell lines are laboratory work, not human trials.
5. Thymosin alpha-1: a licensed medicine, for something else
Thymosin alpha-1 is a 28-amino-acid peptide made by the thymus. As the drug thymalfasin (Zadaxin) it is licensed in a number of countries outside the US, mainly as an adjunct in chronic hepatitis, where it has been through clinical trials. Its studied role is immune modulation, not tissue repair, and it is not FDA-approved.
How the evidence compares
| Peptide | Proposed mechanism | Where the human evidence is | Regulatory status |
|---|---|---|---|
| BPC-157 | Nitric oxide signalling, new blood vessels | Two-person safety pilot, uncontrolled knee series, one unpublished bowel trial, one trial recruiting | Not approved anywhere |
| TB-500 | Actin binding, cell migration | Full-length thymosin beta-4 for dry eye and leg ulcers; none for the fragment | Not approved anywhere |
| GHK-Cu | Collagen and repair-gene expression | Topical: diabetic foot ulcers (positive), facial skin (no objective benefit) | Cosmetic ingredient; no approved drug |
| KPV | NF-kB inhibition in gut lining | None published | Not approved anywhere |
| Thymosin alpha-1 | T-cell and dendritic-cell modulation | Clinical trials in hepatitis | Licensed in several countries; not FDA-approved |
Has research looked at BPC-157 and TB-500 together?
BPC-157 and TB-500 are often discussed as a pair. The argument for pairing them is mechanistic: different proposed steps of the same repair process. No study has tested the two together in people. The one preclinical head-to-head published so far (Bicer et al., Joint Diseases and Related Surgery, 2026) found that the combined group did not outperform TB-500 alone. A reasonable mechanistic story is not the same thing as a trial.
The evidence, read by physicians
Two talks from a sports medicine physician going through the literature, and one personal account from someone who stopped. They are commentary, not instruction.
What genetics research does and does not show
Several genes come up in this area because they sit on the pathways these peptides are proposed to act on. NOS3 (rs1799983) is linked to differences in nitric oxide production. MMP3 (rs3025058) is linked to how quickly the extracellular matrix is remodelled. COL1A1 (rs1800012) and COL5A1 (rs12722) are linked in population studies to collagen structure and to tendon and ligament injury risk.
Those are associations with biology and with injury risk. None of them has been tested as a predictor of response to any of these five peptides. No study has tested whether these genotypes change response to BPC-157, TB-500, GHK-Cu, KPV or thymosin alpha-1, in people or in preclinical models. A DNA report can show which versions you carry and what they have been linked to; it says nothing about what any of these peptides would do, because no study has tested that.
One licensed drug, one compound with topical human data, and three with little or none.
Thymosin alpha-1 is a licensed medicine for hepatitis in some countries. GHK-Cu has real but mostly topical human trials. BPC-157, TB-500 and KPV rest largely on preclinical work. None of the five is FDA-approved for tissue repair, and none has a genetic test that predicts response. Decisions about injuries belong with a licensed clinician.
Frequently asked questions
Which peptides have been studied for tissue repair?
The five most discussed are BPC-157, TB-500, GHK-Cu, KPV and thymosin alpha-1. BPC-157 has a large preclinical literature and almost no published human data. TB-500's human trials used the full thymosin beta-4 protein for dry eye and leg ulcers. GHK-Cu has topical human trials. KPV has no published human study. Thymosin alpha-1 is licensed in some countries for hepatitis, not for tissue repair.
Has BPC-157 been tested in humans for healing?
Barely. The published human record is a two-person intravenous safety pilot, a 12-person knee-pain chart review with no control group, and an inflammatory bowel trial (PL-14736) whose results were never published as a standalone paper. A randomized hamstring-strain trial has been recruiting since February 2026 and has not reported.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid peptide from gastric juice, proposed to act through nitric oxide signalling and new blood-vessel growth. TB-500 is a seven-amino-acid fragment of thymosin beta-4, proposed to help cells migrate by binding actin. Their human evidence differs too: TB-500's cited human trials used the full protein for eye and skin conditions.
Have BPC-157 and TB-500 been studied together?
Not in people. The one preclinical head-to-head published so far (Bicer et al., 2026) found that the combined group did not outperform TB-500 alone. The case made for pairing them is a mechanistic argument, not a trial result.
Does DNA predict how well a repair peptide will work?
No study has shown that. NOS3, MMP3, COL1A1 and COL5A1 variants are linked to nitric oxide production, matrix remodelling, collagen structure and injury risk, but none has been tested as a predictor of response to any of these peptides. A DNA report can show which variants you carry and what they have been linked to; no study has tested whether those variants change what any of these peptides does.
This article is for informational and educational purposes only. It reports what published research found; it is not medical advice, it does not diagnose, treat, cure or prevent any disease, and nothing in it is a dose or a recommendation to use any compound. Talk to a licensed clinician about any medical decision.